Acadia Healthcare Co., Inc.

As of November 21, 2025, Acadia Healthcare Co., Inc. is considered undervalued with a P/E ratio of 8, an EV to EBITDA ratio of 6.69, and a Price to Book Value of 0.69, especially when compared to peers like Encompass Health Corp. and The Ensign Group, despite a poor year-to-date return of -61.72%.

As of November 7, 2025, Acadia Healthcare Co., Inc. is considered overvalued with a valuation grade of expensive, reflected by a low P/E ratio of 8 compared to peers and a poor year-to-date return of -54.17%.

As of November 7, 2025, Acadia Healthcare Co., Inc. is considered overvalued with a P/E ratio of 8, significantly lower than its peers, and has experienced a poor year-to-date return of -50.79%, contrasting sharply with the S&P 500's positive return of 14.40%.

As of November 7, 2025, Acadia Healthcare Co., Inc. is considered overvalued with a P/E ratio of 8 and an EV to EBITDA ratio of 6.69, significantly lower than its peers, while also underperforming the S&P 500 with a year-to-date return of -50.79%.

As of October 31, 2025, Acadia Healthcare Co., Inc. is fairly valued with a P/E ratio of 8, but has underperformed the S&P 500 with a year-to-date return of -47.89%.

As of October 31, 2025, Acadia Healthcare Co., Inc. is considered fairly valued and potentially undervalued with a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69, especially when compared to peers like Encompass Health Corp. and The Ensign Group, despite underperforming the S&P 500 with a year-to-date return of -45.78%.

As of October 31, 2025, Acadia Healthcare Co., Inc. is considered fairly valued and potentially undervalued with a P/E ratio of 8, significantly lower than its peers, despite a year-to-date stock performance of -45.78% compared to the S&P 500's 16.30% return.

As of October 17, 2025, Acadia Healthcare Co., Inc. is fairly valued with a low P/E ratio of 8, indicating potential undervaluation compared to peers, but has experienced poor stock performance with a year-to-date return of -39.05% and a three-year return of -70.67%.

As of October 17, 2025, Acadia Healthcare Co., Inc. is considered fairly valued despite its attractive metrics, such as a P/E ratio of 8, indicating potential undervaluation compared to peers, while its year-to-date stock performance has significantly underperformed the S&P 500.

As of October 17, 2025, Acadia Healthcare Co., Inc. is fairly valued with attractive metrics indicating it may be undervalued compared to peers, but its poor stock performance, with a year-to-date return of -39.05%, raises concerns for investors.

As of October 3, 2025, Acadia Healthcare's trend is neutral with mixed signals; it has outperformed the S&P 500 recently but underperformed year-to-date, showing a mildly bullish weekly MACD and a bearish monthly MACD.

As of October 3, 2025, Acadia Healthcare's technical trend is neutral with mixed signals, showing short-term outperformance against the S&P 500 but a significant year-to-date underperformance.

As of October 3, 2025, Acadia Healthcare's technical trend is neutral with mixed signals, showing short-term outperformance against the S&P 500 but a significant year-to-date underperformance.

As of August 27, 2025, Acadia Healthcare Co., Inc. shows a mildly bearish technical trend with mixed signals across indicators, underperforming the S&P 500 significantly year-to-date and over the past year.